Problems in treating patients with high-risk arterial hypertension: focussing on diastolic heart failure
Abstract
Currently, the prevalence of diastolic chronic heart failure (DCHF) in the population of chronic heart failure (CHF) patients reaches 40—55 %, being as high as ≥73 % in Russia. The prevalence of DCHF is higher in older age groups and women. The CHF diagnosis is mostly based on clinical examination of the patient, since a standard assessment of E/A ratio is often not informative enough. Detailed assessment of diastolic function requires measurement of heart wall thickness and atrial sizes during four-chamber position echocardiography. According to the European clinical guidelines, the leading role in diastolic function assessment belongs to E/Em parameter, reflecting early diastolic mitral flow E and early diastolic myocardial relaxation. An increase in E/Em up to 8—15 is a sign of diastolic dysfunction. Despite substantial advances in the treatment of CHF with decreased ejection fraction, currently, there are no medications for the treatment of DCHF with effectiveness demonstrated in largescale randomised clinical trials. Therefore, the present approaches to DCHF treatment remain empirically based.
References
1. Andrew P. Diastolic Heart Failure Demystified. Chest 2003;124:744–53.
2. Zipes. Braunwald’s Heart Disease, 8e, NY. – 2007
3. Драпкина О.М., Ашихмин Я.И. Хроническая сердечная недостаточность с сохраненной фракцией выброса: патофизиология, диагностика, стратегия лечения. Кардиология 2009; 9: 90–5.
4. Brutsaert W, Dirk L, De Keulenaer H, Gilles W. Diastolic heart failure: a myth. Current Opinion in Cardiology 2006; 21(3): 240–8.
5. Petrie MC, Caruana L, Berry C, McMurray JJV. “Diastolic heart failure” or heart failure caused by subtle left ventricular systolic dysfunction? Heart 2002; 87: 29–31.
6. Paulus W, Carsten T, Sanderson J, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007; 28: 2539–50.
7. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251–9.
8. Owan TE, Redfield MM Epidemiology of diastolic heart failure. Prog Cardiovasc Dis 2005; 47: 320.
9. Беленков Ю. Н., Мареев В.Ю., Агеев Ф.Т. Хроническая сердечная недостаточность. Избранные лекции по кардиологии. М., Гэотар-Медиа 2006.
10. Christopher AP, Sándor KJ. The Role of Left Atrial Function in Diastolic Heart Failure. Circ Cardiovasc Imaging 2009; 2: 6–9.
11. Little WC. Heart failure with a normal left ventricular ejection fraction: diastolic heart failure Transactions of the american clinical and climatological association 2008; 119: 93–102.
12. Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П. и др. Национальные Рекомендации ВНОК И ОССН по диагностике и лечению ХСН (второй пересмотр). Серд недостат 2007; 8(2).
13. Cleland JGF, Tendera M, Adamus J, et al. The Perindopril in Elderly People with Chronic Heart Failure (PEP-CHF) Study. Eur Heart J 2006; 27: 2338–45.
14. Aronow W, Kronzon I. Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. Am J Cardiol 1993; 71: 602–4.
15. Carson P, Johnson G, Fletcher R, et al. Mild systolic dysfunction in heart failure: baseline characteristics, prognosis and response to therapy in the Vasodilator in Heart Failure Trials (V-HeFT). JACC 1996; 27: 642–9.
16. Yusuf S, Pfeffer M, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet 2003; 362: 777–81.
17. Massie B, Carson P, John J. McMurray J, et al. Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction. N Engl J Med 2008; 359: 2456–67.
18. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525–33.
19. Flather M, Shibata M, Coats A, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26: 215–25.
20. Ghio S, Magrini G, Serio A, et al. Effect of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. Eur Heart J 2006; 27: 562–8.
21. Smiseth O, Tendera M. Diastolic heart failure Springer-Verlag London 2008; 329.
22. Drapkina O, Ashikhmin Y, Ivashkin V. Ramipril in the nreanment of diastolic dysfunction on the background of metabolic syndrome. J Hypertention 2009; Suppl. (Poster present, ESH congress,2009, Milan) S: 245.
Review
For citations:
Drapkina O.M. Problems in treating patients with high-risk arterial hypertension: focussing on diastolic heart failure. Cardiovascular Therapy and Prevention. 2010;9(3):11-117. (In Russ.)
Views:
486
Email this article 
